Your fact-checks will appear here
Paraguayan newspaper
“Lipoless” is not a single, well-defined medical product in the available reporting; the name appears across at least three different categories — prescription tirzepatide-based therapy marketed in Pa...
Available reporting does not show that a product called "Lipoless" has been approved by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA); a Paraguayan news article as...
Available reporting shows Lipoless is a Paraguay‑launched, locally produced tirzepatide product marketed for obesity and diabetes, but I found no clinical trial records or peer‑reviewed study results ...
Available reporting describes Lipoless as a Paraguayan, tirzepatide‑based product launched in 2025 for obesity and diabetes care, sold in six subcutaneous dose strengths for home use (2.5–15 mg) . Pee...